Combining Toripalimab with Chemo-radiotherapy for Advanced Nasopharyngeal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of adding Toripalimab, a PD-1 inhibitor, to concurrent chemo-radiotherapy in patients with unresectable locally recurrent nasopharyngeal carcinoma. Participants are randomly assigned to receive either the combination treatment or chemo-radiotherapy alone. The study aims to compare the efficacy and safety outcomes between these two groups to determine if the addition of PD-1 treatment can reduce disease progression and improve survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed recurrent nasopharyngeal carcinoma.
2. The recurrence time is more than 12 months from the end of the first course of radiotherapy.
3. Tumor staged as rT2-4N0-3M0，rII-IVa (according to the 8th AJCC edition).
4. Subjects must have a measurable disease by CT or MRI per RECIST 1.1 criteria.
5. Karnofsky scale (KPS)≥70.
6. Normal bone marrow function.
7. Normal liver and kidney function:

   1. total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit;
   2. creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit.
8. Given written informed consent.

Exclusion Criteria:

1. Resectable nasopharyngeal diseases: rT2 (the tumour is confined in the superficial parapharyngeal spacer and is more than 0.5cm from the internal carotid artery) and rT3 (the tumour is confined in the base wall of the sphenoid sinus and is more than 0.5cm from the internal carotid artery and cavernous sinus).
2. The patients are suffering from severe nasopharyngeal necrosis, radiation induced brain injury, and fibrosis of the neck et. al, who are evaluated as unsuitable for secondary radiotherapy by the researchers.
3. Has known allergy to large molecule protein products or any compound of study therapy.
4. Has known subjects with other malignant tumors.
5. Has any active autoimmune disease or history of autoimmune disease.
6. Has a history of psychiatric substance abuse, alcoholism, or drug addiction.
7. The laboratory examination value does not meet the relevant standards within 7 days before enrollment
8. Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study medication.
9. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year.
10. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.
11. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy). Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) will be allowed to enroll.
12. Has a known history of human immunodeficiency virus (HIV).
13. Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive
14. Has received a live vaccine within 4 weeks of planned start of study therapy
15. Pregnancy or breast feeding

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting
• Wuzhou Red Cross Hospital
  Wuzhou, Guangxi, China Recruiting
• Cancer Center of Guangzhou Medical University
  Guangzhou, Guangdong, China Not yet recruiting
• Yuebei People's Hospital
  Shaoguan, Guangdong, China Not yet recruiting
• Zhongshan People's Hospital
  Zhongshan, Guangdong, China Not yet recruiting
• The Fifth Affiliated Hospital of Sun Yat-sen University
  Zhuhai, Guangdong, China Not yet recruiting

Study contacts

• Study coordinator: Ming-Yuan Chen, MD, PhD
• Email: chmingy@mail.sysu.edu.cn
• Phone: : 86-20-87343624

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Induction chemotherapy with low-dose radiation and cadonilimab for locally advanced nasopharyngeal carcinoma

  This study will try adding low-dose radiation and the immune drug cadonilimab to induction chemotherapy before standard concurrent chemoradiotherapy in adults with newly diagnosed locally advanced nasopharyngeal carcinoma.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 2 other locations · NCT05941741

• Comparing reduced and conventional radiotherapy doses for nasopharyngeal carcinoma

  This study is testing whether a lower dose of radiotherapy is just as effective and safe as the standard dose for patients with stage II-III nasopharyngeal cancer who have already received chemotherapy.

  Recruiting at 2 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT04448522

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Tracking fluid buildup (edema) in people with cancer

  This will try segmental bioelectrical impedance analysis to see if it can monitor local fluid buildup in cancer patients who have arm or leg swelling after radiotherapy or chemotherapy.

  Recruiting University of Copenhagen · Aalborg, The North Denmark Region · NCT07443618

• Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer

  This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.

  Recruiting Tata Memorial Hospital · Mumbai, Maharashtra · NCT07400809

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.